Printer Friendly

Research and Markets: Eosinophilic Esophagitis - Pipeline Review, H2 2012.

DUBLIN -- Research and Markets ( has announced the addition of Global Markets Direct's new report "Eosinophilic Esophagitis - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Eosinophilic Esophagitis - Pipeline Review, H2 2012', provides an overview of the Eosinophilic Esophagitis therapeutic pipeline. This report provides information on the therapeutic development for Eosinophilic Esophagitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis. '


- A snapshot of the global therapeutic scenario for Eosinophilic Esophagitis.

- A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Eosinophilic Esophagitis pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

-Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Eosinophilic Esophagitis therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit

Source: Global Markets Direct
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 27, 2012
Previous Article:Research and Markets: Inherited Metabolic Disorders - Pipeline Review, H2 2012.
Next Article:Gregory J. Fleming to Speak at the Goldman Sachs 2012 Financial Services Conference.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters